Compositions for treating joints comprising bone morphogenetic protein and hyaluronic acid
First Claim
Patent Images
1. A composition for treating a joint condition, comprising:
- an injectable formulation comprising a precipitate of a bone morphogenetic protein (BMP) dispersed within a solution of hyaluronic acid (HA), the injectable formulation having a concentration of BMP in the range of about 5 μ
g/ml to about 90 μ
g/ml and a concentration of HA in the range of about 5 mg/ml to about 60 mg/ml, and the BMP being in its precipitated form and capable of becoming solubilized and biologically active after injection into an organism.
2 Assignments
0 Petitions
Accused Products
Abstract
Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.
-
Citations
19 Claims
-
1. A composition for treating a joint condition, comprising:
an injectable formulation comprising a precipitate of a bone morphogenetic protein (BMP) dispersed within a solution of hyaluronic acid (HA), the injectable formulation having a concentration of BMP in the range of about 5 μ
g/ml to about 90 μ
g/ml and a concentration of HA in the range of about 5 mg/ml to about 60 mg/ml, and the BMP being in its precipitated form and capable of becoming solubilized and biologically active after injection into an organism.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
12. A kit, comprising:
-
a first component comprising a solution of hyaluronic acid (HA); a second component comprising an amount of a bone morphogenetic protein (BMP), the BMP configured to form a precipitate when mixed with the HA and capable of becoming solubilized and biologically active after injection into an organism; and a syringe for injecting a mixture of the first component and the second component, wherein the mixture has a concentration of BMP in the range of about 5 μ
g/ml to about 90 μ
g/ml and a concentration of HA in the range of about 5 mg/ml to about 60 mg/ml. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19)
-
Specification